Dobromir Dobrev

List of Publications by Year in Descending Order

271 papers	29,392 citations	75 h-index	169 g-index
379 ext. papers	37,643 ext. citations	6.8 avg, IF	6.94 L-index

#	Paper	IF	Citations
271	Geschlechtsspezifische Unterschiede in der Pharmakologie. *Aktuelle Kardiologie*, **2022**, 11, 62-66	0.1	
270	Conditional immortalization of human atrial myocytes for the generation of in vitro models of atrial fibrillation.. *Nature Biomedical Engineering*, **2022**,	19	1
269	Landscape alteration affects the demography of an endangered avian predator by reducing the habitat quality. *Avian Research*, **2022**, 100030	2	2
268	Researchers in cardiology - Why and how to get on Twitter?. *IJC Heart and Vasculature*, **2022**, 40, 101010	2.4	0
267	Genetic inhibition of Nuclear Factor of Activated T-cell c2 (NFATc2) prevents atrial fibrillation in CREM transgenic mice. *Cardiovascular Research*, **2021**,	9.9	1
266	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. *Europace*, **2021**, 23, 329-344	3.9	14
265	SPEG: a key regulator of cardiac calcium homeostasis. *Cardiovascular Research*, **2021**, 117, 2175-2185	9.9	5
264	Postoperative Atrial Fibrillation: Features, Mechanisms, and Clinical Management. *Cardiac Electrophysiology Clinics*, **2021**, 13, 123-132	1.4	3
263	Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it. *Cardiovascular Research*, **2021**, 117, 1616-1631	9.9	5
262	Inositol Trisphosphate Receptors and Nuclear Calcium in Atrial Fibrillation. *Circulation Research*, **2021**, 128, 619-635	15.7	6
261	The impact of Twitter promotion on future citation rates: The #TweetTheJournal study. *IJC Heart and Vasculature*, **2021**, 33, 100776	2.4	3
260	Atrial fibrillation after cardiac surgery: A systematic review and meta-analysis. *Journal of Thoracic and Cardiovascular Surgery*, **2021**,	1.5	3
259	Oxidative stress: a bystander or a causal contributor to atrial remodelling and fibrillation?. *Cardiovascular Research*, **2021**, 117, 2291-2293	9.9	4
258	Pericardial adipose tissue: An emerging biomarker of atrial fibrillation?. *International Journal of Cardiology*, **2021**, 331, 122-123	3.2	
257	Cellular Mechanisms of the Anti-Arrhythmic Effect of Cardiac PDE2 Overexpression. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
256	Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation. *Cardiovascular Research*, **2021**, 117, 1609-1611	9.9	1
255	Mapping genetic changes in the cAMP-signaling cascade in human atria. *Journal of Molecular and Cellular Cardiology*, **2021**, 155, 10-20	5.8	3

254	ESC working group on cardiac cellular electrophysiology position paper: relevance, opportunities, and limitations of experimental models for cardiac electrophysiology research. *Europace*, **2021**, 23, 1795-1814	3.9	3
253	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the	9.5	1676
252	Kv1.1 potassium channel subunit deficiency alters ventricular arrhythmia susceptibility, contractility, and repolarization. *Physiological Reports*, **2021**, 9, e14702	2.6	3
251	The crosstalk between cardiomyocyte calcium and inflammasome signaling pathways in atrial fibrillation. *Pflugers Archiv European Journal of Physiology*, **2021**, 473, 389-405	4.6	3
250	NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias. *Cardiovascular Research*, **2021**, 117, 1746-1759	9.9	13
249	Surgery-related cardiac stress: A susceptibility test of late atrial fibrillation recurrence?. *IJC Heart and Vasculature*, **2021**, 32, 100693	2.4	0
248	Does gut microbiota affect atrial rhythm? Causalities and speculations. *European Heart Journal*, **2021**, 42, 3521-3525	9.5	3
247	Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
246	Atrial-Specific LKB1 Knockdown Represents a Novel Mouse Model of Atrial Cardiomyopathy With Spontaneous Atrial Fibrillation. *Circulation*, **2021**, 144, 909-912	16.7	2
245	Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. *Cardiovascular Research*, **2021**,	9.9	6
244	Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation. *Circulation Research*, **2021**, 129, 804-820	15.7	2
243	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. *European Heart Journal*, **2021**,	9.5	3
242	On-demand mobile health infrastructures to allow comprehensive remote atrial fibrillation and risk factor management through teleconsultation. *Clinical Cardiology*, **2020**, 43, 1232-1239	3.3	21
241	CaMKII activity contributes to homeometric autoregulation of the heart: A novel mechanism for the Anrep effect. *Journal of Physiology*, **2020**, 598, 3129-3153	3.9	8
240	Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective. *Circulation Research*, **2020**, 127, 51-72	15.7	87
239	Left-ventricular innervation assessed by I-SPECT/CT is associated with cardiac events in inherited arrhythmia syndromes. *International Journal of Cardiology*, **2020**, 312, 129-135	3.2	1
238	Berücksichtigung QTc-verlängerndes Potenzial: Vor Einleitung einer Therapie mit Antibiotika, Antipsychotika, Antiarrhythmika soll die Gefahr einer klinisch relevanten QTc-Verlängerung geprüft werden. *Kardiologe*, **2020**, 14, 32-34	0.6	1
237	Cardiomyocyte calcium handling in health and disease: Insights from in vitro and in silico studies. *Progress in Biophysics and Molecular Biology*, **2020**, 157, 54-75	4.7	32

236	Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects. *Nature Communications*, **2020**, 11, 1733	17.4	15
235	Altered calcium handling produces reentry-promoting action potential alternans in atrial fibrillation-remodeled hearts. *JCI Insight*, **2020**, 5,	9.9	12
234	Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study. *IJC Heart and Vasculature*, **2020**, 29, 100573	2.4	1
233	Sleep apnea and atrial fibrillation: Update 2020. *IJC Heart and Vasculature*, **2020**, 31, 100681	2.4	0
232	Main mortality factors for the Eastern Imperial Eagle (Aquila heliaca Savigny, 1809) in Bulgaria. *Ornis Hungarica*, **2020**, 28, 120-134	0.5	3
231	Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart. *Basic Research in Cardiology*, **2020**, 115, 10	11.8	24
230	Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. *IJC Heart and Vasculature*, **2020**, 26, 100461	2.4	1
229	Smart device-based detection of atrial fibrillation: Opportunities and challenges in the emerging world of digital health. *International Journal of Cardiology*, **2020**, 302, 108-109	3.2	1
228	The role of amiodarone in contemporary management of complex cardiac arrhythmias. *Pharmacological Research*, **2020**, 151, 104521	10.2	20
227	COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. *IJC Heart and Vasculature*, **2020**, 30, 100631	2.4	47
226	Loss of SPEG Inhibitory Phosphorylation of Ryanodine Receptor Type-2 Promotes Atrial Fibrillation. *Circulation*, **2020**, 142, 1159-1172	16.7	20
225	Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation. *Circulation Research*, **2020**, 127, 1036-1055	15.7	43
224	Acute effects of alcohol on cardiac electrophysiology and arrhythmogenesis: Insights from multiscale in silico analyses. *Journal of Molecular and Cellular Cardiology*, **2020**, 146, 69-83	5.8	10
223	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). *European Heart Journal*, **2020**, 41, 655-720	9.5	267
222	Maastricht antiarrhythmic drug evaluator (MANTA): A computational tool for better understanding of antiarrhythmic drugs. *Pharmacological Research*, **2019**, 148, 104444	10.2	9
221	Computational modeling: What does it tell us about atrial fibrillation therapy?. *International Journal of Cardiology*, **2019**, 287, 155-161	3.2	15
220	Loss of Protein Phosphatase 1 Regulatory Subunit PPP1R3A Promotes Atrial Fibrillation. *Circulation* , **2019**, 140, 681-693	16.7	28
219	Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease?. *IJC Heart and Vasculature*, **2019**, 23, 100369	2.4	1

218	Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants. *Pharmacological Research*, **2019**, 145, 104257	10.2	4
217	Ablation of the calpain-targeted site in cardiac myosin binding protein-C is cardioprotective during ischemia-reperfusion injury. *Journal of Molecular and Cellular Cardiology*, **2019**, 129, 236-246	5.8	12
216	Use of pulsed electron avalanche knife (PEAK) PlasmaBlade in patients undergoing implantation of subcutaneous implantable cardioverter-defibrillator. *IJC Heart and Vasculature*, **2019**, 24, 100390	2.4	1
215	Postoperative atrial fibrillation: mechanisms, manifestations and management. *Nature Reviews Cardiology*, **2019**, 16, 417-436	14.8	106
214	EHRA White Paper: knowledge gaps in arrhythmia management-status 2019. *Europace*, **2019**, 21, 993-994	3.9	23
213	Nightly sleep apnea severity in patients with atrial fibrillation: Potential applications of long-term sleep apnea monitoring. *IJC Heart and Vasculature*, **2019**, 24, 100424	2.4	15
212	Role of autonomic nervous system in atrial fibrillation. *International Journal of Cardiology*, **2019**, 287, 181-188	3.2	41
211	DPP10 is a new regulator of Nav1.5 channels in human heart. *International Journal of Cardiology*, **2019**, 284, 68-73	3.2	2
210	Role of inflammatory signaling in atrial fibrillation. *International Journal of Cardiology*, **2019**, 287, 195-200	3.2	44
209	Translational Challenges in Atrial Fibrillation. *Circulation Research*, **2018**, 122, 752-773	15.7	74
208	Ectopic expression of S28A-mutated Histone H3 modulates longevity, stress resistance and cardiac function in Drosophila. *Scientific Reports*, **2018**, 8, 2940	4.9	10
207	Muscarinic type-1 receptors contribute to I in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation. *International Journal of Cardiology*, **2018**, 255, 61-68	3.2	13
206	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. *Europace*, **2018**, 20, 395-407	3.9	66
205	Identification of optimal reference genes for transcriptomic analyses in normal and diseased human heart. *Cardiovascular Research*, **2018**, 114, 247-258	9.9	23
204	The Molecular Pathophysiology of Atrial Fibrillation **2018**, 396-408		
203	Sex-specific density of ventricular SK currents: is this a general feature of SK channel function?. *Journal of Physiology*, **2018**, 596, 4287	3.9	1
202	Mouse Models of Cardiac Arrhythmias. *Circulation Research*, **2018**, 123, 332-334	15.7	18
201	Ion channels as part of macromolecular multiprotein complexes : Clinical significance. *Herzschrittmachertherapie Und Elektrophysiologie*, **2018**, 29, 30-35	0.8	4

200	Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation. *Frontiers in Physiology*, **2018**, 9, 1383	4.6	39
199	Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging. *IJC Heart and Vasculature*, **2018**, 21, 11-15	2.4	19
198	Cardiomyocyte Inflammasome Signaling in Cardiomyopathies and Atrial Fibrillation: Mechanisms and Potential Therapeutic Implications. *Frontiers in Physiology*, **2018**, 9, 1115	4.6	28
197	Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. *Circulation*, **2018**, 138, 2227-2242	16.7	174
196	Regulation of heterotrimeric G-protein signaling by NDPK/NME proteins and caveolins: an update. *Laboratory Investigation*, **2018**, 98, 190-197	5.9	7
195	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. *Heart Rhythm*, **2017**, 14, e3-e40	6.7	138
194	Gu□ ESC 2016 sobre el diagn□stico y tratamiento de la fibrilaci□ auricular, desarrollada en colaboraci□ con la EACTS. *Revista Espanola De Cardiologia*, **2017**, 70, 50.e1-50.e84	1.5	6
193	Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. *European Heart Journal*, **2017**, 38, 1764-1774	9.5	55
192	Serine/Threonine Phosphatases in Atrial Fibrillation. *Journal of Molecular and Cellular Cardiology*, **2017**, 103, 110-120	5.8	25
191	Calcium-mediated cellular triggered activity in atrial fibrillation. *Journal of Physiology*, **2017**, 595, 4001-4008	5.9	32
190	Controversies About Atrial Fibrillation Mechanisms: Aiming for Order in Chaos and Whether it Matters. *Circulation Research*, **2017**, 120, 1396-1398	15.7	49
189	Chronic loss of inhibitor-1 diminishes cardiac RyR2 phosphorylation despite exaggerated CaMKII activity. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2017**, 390, 857-862	3.4	9
188	Calcium Signaling and Cardiac Arrhythmias. *Circulation Research*, **2017**, 120, 1969-1993	15.7	207
187	The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in goat and dog models. *British Journal of Pharmacology*, **2017**, 174, 2576-2590	8.6	12
186	Differential regulation of protein phosphatase 1 (PP1) isoforms in human heart failure and atrial fibrillation. *Basic Research in Cardiology*, **2017**, 112, 43	11.8	20
185	Nucleoside Diphosphate Kinase-C Suppresses cAMP Formation in Human Heart Failure. *Circulation*, **2017**, 135, 881-897	16.7	16
184	Revealing kinetics and state-dependent binding properties of I-targeting drugs that maximize atrial fibrillation selectivity. *Chaos*, **2017**, 27, 093918	3.3	13
183	JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate. *Cardiovascular Research*, **2017**, 113, 310-320	9.9	28

182	Response to: "The emerging role of hybrid ablation for ablation" by Spartialis M. et al. *International Journal of Cardiology*, **2017**, 249, 258	3.2	
181	Enhanced Activation of Inflammasome Promotes Atrial Fibrillation. *Journal of Molecular and Cellular Cardiology*, **2017**, 112, 147	5.8	3
180	Investigational antiarrhythmic agents: promising drugs in early clinical development. *Expert Opinion on Investigational Drugs*, **2017**, 26, 897-907	5.9	21
179	Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics. *Journal of Physiology*, **2017**, 595, 2229-2252	3.9	51
178	Assessment of Efficacy and Safety of I Inhibitors in Chronic Atrial Fibrillation: Role of Kinetics and State-Dependence of Drug Binding. *Frontiers in Pharmacology*, **2017**, 8, 799	5.6	17
177	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *European Heart Journal*, **2016**, 37, 2893-2962	9.5	4465
176	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace*, **2016**, 18, 1609-1678	3.9	1293
175	Response to Letter Regarding Article, "Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation". *Circulation*, **2016**, 133, e440-1	16.7	4
174	Regulating the regulator: Insights into the cardiac protein phosphatase 1 interactome. *Journal of Molecular and Cellular Cardiology*, **2016**, 101, 165-172	5.8	25
173	Dysfunction of the □-spectrin-based pathway in human heart failure. *American Journal of Physiology - Heart and Circulatory Physiology*, **2016**, 310, H1583-91	5.2	17
172	Gu□ ESC 2015 sobre el tratamiento de pacientes con arritmiasventriculares y prevenci□ de la muerte s□bita cardiaca. *Revista Espanola De Cardiologia*, **2016**, 69, 176.e1-176.e77	1.5	11
171	S-glutathiolation impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure. *FASEB Journal*, **2016**, 30, 1849-64	0.9	22
170	The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. *Cardiovascular Research*, **2016**, 109, 467-79	9.9	108
169	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. *Europace*, **2016**, 18, 37-50	3.9	90
168	An update on atrial fibrillation in 2014: From pathophysiology to treatment. *International Journal of Cardiology*, **2016**, 203, 22-9	3.2	45
167	Differences in Left Versus Right Ventricular Electrophysiological Properties in Cardiac Dysfunction and Arrhythmogenesis. *Arrhythmia and Electrophysiology Review*, **2016**, 5, 14-9	3.2	19
166	Computational models of atrial cellular electrophysiology and calcium handling, and their role in atrial fibrillation. *Journal of Physiology*, **2016**, 594, 537-53	3.9	34
165	Hot Under the Collar **2016**,		35

164	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. *Europace*, **2016**, 18, 1455-1490	3.9	268
163	Challenges to the translation of basic science findings to atrial fibrillation therapies. *Future Cardiology*, **2016**, 12, 251-4	1.3	1
162	Diet is not related to productivity but to territory occupancy in a declining population of Egyptian Vultures Neophron percnopterus. *Bird Conservation International*, **2016**, 26, 273-285	1.7	7
161	The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology. *Journal of Molecular and Cellular Cardiology*, **2016**, 94, 95-106	5.8	15
160	Atrial-Selective Potassium Channel Blockers. *Cardiac Electrophysiology Clinics*, **2016**, 8, 411-21	1.4	24
159	EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. *Journal of Arrhythmia*, **2016**, 32, 247-78	1.5	59
158	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *European Journal of Cardio-thoracic Surgery*, **2016**, 50, e1-e88	3	589
157	Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. *Nature Reviews Cardiology*, **2016**, 13, 575-90	14.8	89
156	Current controversies in determining the main mechanisms of atrial fibrillation. *Journal of Internal Medicine*, **2016**, 279, 428-38	10.8	49
155	Identification of microRNA-mRNA dysregulations in paroxysmal atrial fibrillation. *International Journal of Cardiology*, **2015**, 184, 190-197	3.2	32
154	Expression and function of Kv1.1 potassium channels in human atria from patients with atrial fibrillation. *Basic Research in Cardiology*, **2015**, 110, 505	11.8	25
153	Loss of cardiomyocyte integrin-linked kinase produces an arrhythmogenic cardiomyopathy in mice. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 921-32	6.4	14
152	Atrial Fibrillation Activates AMP-Dependent Protein Kinase and its Regulation of Cellular Calcium Handling: Potential Role in Metabolic Adaptation and Prevention of Progression. *Journal of the American College of Cardiology*, **2015**, 66, 47-58	15.1	54
151	Upregulation of K(2P)3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation. *Circulation*, **2015**, 132, 82-92	16.7	120
150	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Europace*, **2015**, 17, 1601-87	3.9	426
149	Nucleoside diphosphate kinase B-activated intermediate conductance potassium channels are critical for neointima formation in mouse carotid arteries. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1852-61	9.4	12
148	Methods for isolating atrial cells from large mammals and humans. *Journal of Molecular and Cellular Cardiology*, **2015**, 86, 187-98	5.8	15
147	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *European Heart Journal*, **2015**, 36, 2793-2867	9.5	2187

146	The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results. *Europace*, **2015**, 17, 1457-66	3.9	4
145	New antiarrhythmic targets in atrial fibrillation. *Future Cardiology*, **2015**, 11, 645-54	1.3	2
144	Application of the RIMARC algorithm to a large data set of action potentials and clinical parameters for risk prediction of atrial fibrillation. *Medical and Biological Engineering and Computing*, **2015**, 53, 263-73	3.1	16
143	Studying the demographic drivers of an increasing Imperial Eagle population to inform conservation management. *Biodiversity and Conservation*, **2015**, 24, 627-639	3.4	14
142	Calcium Handling Abnormalities as a Target for Atrial Fibrillation Therapeutics: How Close to Clinical Implementation?. *Journal of Cardiovascular Pharmacology*, **2015**, 66, 515-22	3.1	12
141	Pathopysiologie des Vorhofflimmerns. *CardioVasc*, **2015**, 15, 36-40	0	1
140	Counteracting Protein Kinase Activity in the Heart: The Multiple Roles of Protein Phosphatases. *Frontiers in Pharmacology*, **2015**, 6, 270	5.6	30
139	Dysfunction in the β spectrin-dependent cytoskeleton underlies human arrhythmia. *Circulation*, **2015**, 131, 695-708	16.7	41
138	Fibroblast inward-rectifier potassium current upregulation in profibrillatory atrial remodeling. *Circulation Research*, **2015**, 116, 836-45	15.7	64
137	Alterations in the interactome of serine/threonine protein phosphatase type-1 in atrial fibrillation patients. *Journal of the American College of Cardiology*, **2015**, 65, 163-73	15.1	31
136	Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. *Circulation Research*, **2014**, 114, 1483-99	15.7	373
135	Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease. *Circulation Research*, **2014**, 114, 1311-9; discussion 1319	15.7	101
134	Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling. *Journal of Molecular and Cellular Cardiology*, **2014**, 77, 113-24	5.8	36
133	Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. *Circulation*, **2014**, 129, 145-156	16.7	273
132	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European Heart Journal*, **2014**, [illegible]	9.5	3467
131	Cardiac CaM Kinase II genes δ and γ contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy. *Circulation*, **2014**, 130, 1262-73	16.7	115
130	The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. *Circulation Research*, **2014**, 114, 1453-68	15.7	587
129	MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. *Circulation Research*, **2014**, 114, 689-705	15.7	93

128	Cardiac safety assays. *Current Opinion in Pharmacology*, **2014**, 15, 16-21	5.1	30
127	Survival rate and mortality of juvenile and immature eastern imperial eagles (Aquila heliaca) from Bulgaria studied by satellite telemetry. *Slovak Raptor Journal*, **2014**, 8, 53-60		4
126	Calcium dysregulation in atrial fibrillation: the role of CaMKII. *Frontiers in Pharmacology*, **2014**, 5, 30	5.6	35
125	Constitutive activity of the acetylcholine-activated potassium current IK,ACh in cardiomyocytes. *Advances in Pharmacology*, **2014**, 70, 393-409	5.7	25
124	Loss of microRNA-106b-25 cluster promotes atrial fibrillation by enhancing ryanodine receptor type-2 expression and calcium release. *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 1214-22	6.4	78
123	Ryanodine receptor-mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model. *Circulation*, **2014**, 129, 1276-1285	16.7	114
122	Impaired local regulation of ryanodine receptor type 2 by protein phosphatase 1 promotes atrial fibrillation. *Cardiovascular Research*, **2014**, 103, 178-87	9.9	49
121	Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. *Circulation*, **2014**, 129, 430-40	16.7	123
120	2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European Journal of Cardio-thoracic Surgery*, **2014**, 46, 517-92	3	588
119	The Molecular Pathophysiology of Atrial Fibrillation **2014**, 449-458		0
118	Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. *Journal of Clinical Investigation*, **2014**, 124, 4759-72	15.9	77
117	Conservation measures undertaken to improve the population status of eastern imperial eagle (Aquila heliaca) in Bulgaria. *Slovak Raptor Journal*, **2014**, 8, 27-39		9
116	Cholinergic and Constitutive Regulation of Atrial Potassium Channel **2014**, 383-391		
115	Electrical storm: recent pathophysiological insights and therapeutic consequences. *Basic Research in Cardiology*, **2013**, 108, 336	11.8	24
114	Function and regulation of serine/threonine phosphatases in the healthy and diseased heart. *Journal of Molecular and Cellular Cardiology*, **2013**, 64, 90-8	5.8	83
113	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. *Europace*, **2013**, 15, 1540-56	3.9	101
112	Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization. *Journal of the American College of Cardiology*, **2013**, 62, 2010-9	15.1	120
111	Impaired Na+-dependent regulation of acetylcholine-activated inward-rectifier K+ current modulates action potential rate dependence in patients with chronic atrial fibrillation. *Journal of Molecular and Cellular Cardiology*, **2013**, 61, 142-52	5.8	30

110	Rhythm control of atrial fibrillation in heart failure. *Heart Failure Clinics*, **2013**, 9, 407-15, vii-viii	3.3	6
109	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. *Journal of the American College of Cardiology*, **2013**, 62, 1596-606	15.1	88
108	New directions in antiarrhythmic drug therapy for atrial fibrillation. *Future Cardiology*, **2013**, 9, 71-88	1.3	36
107	MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. *Circulation*, **2013**, 127, 1466-75, 1475e1-28	16.7	178
106	Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. *Journal of the American College of Cardiology*, **2013**, 62, 68-77	15.1	185
105	T-type calcium current contributes to escape automaticity and governs the occurrence of lethal arrhythmias after atrioventricular block in mice. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 799-808	6.4	17
104	Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation. *Circulation*, **2013**, 128, 1748-57	16.7	186
103	NSC23766, a widely used inhibitor of Rac1 activation, additionally acts as a competitive antagonist at muscarinic acetylcholine receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2013** , 347, 69-79	4.7	54
102	Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. *Clinical Medicine Insights: Cardiology*, **2013**, 7, 127-40	3.2	18
101	Isolation of human atrial myocytes for simultaneous measurements of Ca2+ transients and membrane currents. *Journal of Visualized Experiments*, **2013**, e50235	1.6	11
100	Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. *Vascular Health and Risk Management*, **2013**, 9, 165-75	4.4	13
99	The European Network for Translational Research in Atrial Fibrillation. *Clinical Investigation*, **2012**, 2, 1061-1067		
98	Voltage-gated Na+ channels: novel players in fibroblast-to-myofibroblast transition with a potential role in atrial arrhythmogenesis?. *Journal of Physiology*, **2012**, 590, 4975	3.9	3
97	Novel molecular targets for atrial fibrillation therapy. *Nature Reviews Drug Discovery*, **2012**, 11, 275-91	64.1	140
96	Palmitoylation and membrane association of the stress axis regulated insert (STREX) controls BK channel regulation by protein kinase C. *Journal of Biological Chemistry*, **2012**, 287, 32161-71	5.4	41
95	Calcium handling and atrial fibrillation. *Wiener Medizinische Wochenschrift*, **2012**, 162, 287-91	2.9	21
94	The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. *European Heart Journal*, **2012**, 33, 1870-7	9.5	128
93	The impact of rapid atrial pacing on ADMA and endothelial NOS. *International Journal of Cardiology*, **2012**, 154, 141-6	3.2	55

92	Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. *Circulation*, **2012**, 126, 2051-64	16.7	185
91	Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. *Circulation*, **2012**, 125, 2059-70	16.7	395
90	Role of RyR2 phosphorylation at S2814 during heart failure progression. *Circulation Research*, **2012**, 110, 1474-83	15.7	158
89	Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. *Circulation Research*, **2012**, 110, 465-70	15.7	109
88	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. *Europace*, **2012**, 14, 8-27	3.9	156
87	Cellular and molecular correlates of ectopic activity in patients with atrial fibrillation. *Europace*, **2012**, 14 Suppl 5, v97-v105	3.9	9
86	Proarrhythmic atrial calcium cycling in the diseased heart. *Advances in Experimental Medicine and Biology*, **2012**, 740, 1175-91	3.6	11
85	Enhanced myofilament responsiveness upon β-adrenergic stimulation in post-infarct remodeled myocardium. *Journal of Molecular and Cellular Cardiology*, **2011**, 50, 487-99	5.8	24
84	The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. *Cardiovascular Research*, **2011**, 89, 734-43	9.9	80
83	Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. *Cardiovascular Research*, **2011**, 91, 420-8	9.9	15
82	Defects in ankyrin-based membrane protein targeting pathways underlie atrial fibrillation. *Circulation*, **2011**, 124, 1212-22	16.7	78
81	Differential protein kinase C isoform regulation and increased constitutive activity of acetylcholine-regulated potassium channels in atrial remodeling. *Circulation Research*, **2011**, 109, 1031-43	15.7	69
80	Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. *Circulation*, **2011**, 123, 137-46	16.7	113
79	Ca(2+)-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. *Circulation*, **2011**, 123, 2192-203	16.7	43
78	No evidence for an association between the rs2824292 variant at chromosome 21q21 and ventricular fibrillation during acute myocardial infarction in a German population. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 1237-9	5.9	11
77	Recent advances in the molecular pathophysiology of atrial fibrillation. *Journal of Clinical Investigation*, **2011**, 121, 2955-68	15.9	369
76	Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation. *Circulation Research*, **2011**, 109, 1055-66	15.7	238
75	Phosphatase-1 inhibitor-1 in physiological and pathological β-adrenoceptor signalling. *Cardiovascular Research*, **2011**, 91, 392-401	9.9	41

74	Transverse tubules are a common feature in large mammalian atrial myocytes including human. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 301, H1996-2005	5.2	103
73	Oxidized CaMKII causes cardiac sinus node dysfunction in mice. *Journal of Clinical Investigation*, **2011**, 121, 3277-88	15.9	154
72	Ion Channel Remodelling in Atrial Fibrillation. *European Cardiology Review*, **2011**, 7, 97	3.9	7
71	Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. *British Journal of Pharmacology*, **2010**, 159, 1581-3	8.6	21
70	Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. *Circulation: Arrhythmia and Electrophysiology*, **2010**, 3, 530-41	6.4	83
69	Animal models for atrial fibrillation: clinical insights and scientific opportunities. *Europace*, **2010**, 12, 160-72	3.9	112
68	Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2010**, 3, 472-80	6.4	154
67	New antiarrhythmic drugs for treatment of atrial fibrillation. *Lancet, The*, **2010**, 375, 1212-23	40	210
66	Voltage-clamp-based methods for the detection of constitutively active acetylcholine-gated I(K,ACh) channels in the diseased heart. *Methods in Enzymology*, **2010**, 484, 653-75	1.7	14
65	Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2010**, 381, 251-9	3.4	38
64	Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2010**, 381, 195-206	3.4	33
63	Calmodulin kinase II, sarcoplasmic reticulum Ca2+ leak, and atrial fibrillation. *Trends in Cardiovascular Medicine*, **2010**, 20, 30-4	6.9	29
62	Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. *Journal of Clinical Investigation*, **2010**, 120, 617-26	15.9	71
61	Role of abnormal sarcoplasmic reticulum function in atrial fibrillation. *Therapy: Open Access in Clinical Medicine*, **2010**, 7, 147-158		4
60	Ion channel portrait of the human sinus node: useful for a better understanding of sinus node function and dysfunction in humans?. *Circulation*, **2009**, 119, 1556-8	16.7	7
59	Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. *European Heart Journal*, **2009**, 30, 1411-20	9.5	99
58	Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. *Journal of Molecular and Cellular Cardiology*, **2009**, 46, 385-94	5.8	78
57	Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery. *Cardiovascular Therapeutics*, **2009**, 27, 223-5	3.3	1

56	Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. *Cardiovascular Research*, **2009**, 81, 491-9	9.9	73
55	Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. *Journal of Clinical Investigation*, **2009**, 119, 1940-51	15.9	279
54	Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. *Heart Rhythm*, **2008**, 5, 1047-54	6.7	100
53	Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 62-73	6.4	704
52	Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. *Cardiovascular Research*, **2008**, 80, 396-406	9.9	87
51	Digital lock-in techniques for adaptive power-line interference extraction. *Physiological Measurement*, **2008**, 29, 803-16	2.9	8
50	Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 93-102	6.4	205
49	Four and a half LIM protein 1: a novel chaperone for atrium-specific Kv1.5 channels with a potential role in atrial arrhythmogenesis. *Cardiovascular Research*, **2008**, 78, 411-2	9.9	6
48	Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. *Circulation Research*, **2008**, 103, 845-54	15.7	142
47	Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. *Journal of Cardiovascular Pharmacology*, **2008**, 52, 293-9	3.1	86
46	New concepts in understanding and modulating atrial repolarisation in patients with atrial fibrillation. *Journal of Interventional Cardiac Electrophysiology*, **2008**, 22, 107-10	2.4	3
45	The German Competence Network on Atrial Fibrillation (AFNET). *Herz*, **2008**, 33, 548-55	2.6	7
44	Changes in I K, ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. *Cardiovascular Research*, **2008**, 77, 35-43	9.9	69
43	Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2007**, 375, 383-92	3.4	60
42	Vascular large conductance calcium-activated potassium channels: functional role and therapeutic potential. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2007**, 376, 145-55	3.4	82
41	Cardiomyocyte Ca2+ overload in atrial tachycardia: is blockade of L-type Ca2+ channels a promising approach to prevent electrical remodeling and arrhythmogenesis?. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2007**, 376, 227-30	3.4	7
40	Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK,ACh channels in patients with chronic atrial fibrillation. *Cardiovascular Research*, **2007**, 74, 426-37	9.9	91
39	5-hydroxytryptamine and atrial arrhythmogenesis: a "culprit mechanism" or bystander in patients with chronic atrial fibrillation?. *Journal of Molecular and Cellular Cardiology*, **2007**, 42, 51-3	5.8	3

38	Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. *Journal of Molecular and Cellular Cardiology*, **2007**, 43, 223-9	5.8	124
37	Novel anti-arrhythmic agents for the treatment of atrial fibrillation. *Current Opinion in Pharmacology*, **2007**, 7, 214-8	5.1	11
36	Electrical remodeling in atrial fibrillation. *Herz*, **2006**, 31, 108-12; quiz 142-3	2.6	38
35	Do genetics help to better understand the underlying mechanisms of atrial fibrillation?. *European Heart Journal*, **2006**, 27, 1640-1	9.5	3
34	Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. *Circulation*, **2006**, 114, 670-80	16.7	200
33	Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. *Biochemical and Biophysical Research Communications*, **2006**, 346, 700-6	3.4	53
32	Quantification of G protein Gaalphas subunit splice variants in different human tissues and cells using pyrosequencing. *Gene Expression*, **2005**, 12, 69-81	3.4	13
31	Effects of Immunoglobulin G from Patients with Dilated Cardiomyopathy on Rat Cardiomyocytes. *Basic and Clinical Pharmacology and Toxicology*, **2005**, 96, 445-452	3.1	8
30	Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays. *Journal of Thoracic and Cardiovascular Surgery*, **2005**, 129, 1383-90	1.5	84
29	Defective cardiac ryanodine receptor regulation during atrial fibrillation. *Circulation*, **2005**, 111, 2025-32	16.7	267
28	Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. *Circulation*, **2005**, 112, 471-81	16.7	188
27	Muscarinic subtype-2 receptor autoantibodies: actors or bystanders in human atrial fibrillation?. *European Heart Journal*, **2004**, 25, 1091-2	9.5	7
26	Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. *Circulation*, **2004**, 110, 2299-306	16.7	219
25	Recording atrial monophasic action potentials using standard pacemaker leads: an alternative way to study electrophysiology properties of the human atrium in vivo?. *PACE - Pacing and Clinical Electrophysiology*, **2004**, 27, 1632-7	1.6	1
24	An aqueous extract of the marine sponge Ectyoplasia ferox stimulates L-type Ca2+-current by direct interaction with the Cav1.2 subunit. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2004**, 370, 474-83	3.4	7
23	Mechanisms of beta-adrenergic receptor-mediated venodilation in humans. *Clinical Pharmacology and Therapeutics*, **2004**, 75, 49-59	6.1	20
22	Transcription factors for ion channels: active or passive players in cardiac remodeling?. *Cardiovascular Research*, **2003**, 60, 226-7	9.9	
21	Remodeling of cardiomyocyte ion channels in human atrial fibrillation. *Basic Research in Cardiology*, **2003**, 98, 137-48	11.8	141

20	Therapeutically relevant concentrations of neomycin selectively inhibit P-type Ca2+ channels in rat striatum. *European Journal of Pharmacology*, **2003**, 461, 105-11	5.3	11
19	Cardiac sympathetic innervation and control of potassium channel function. *Journal of Molecular and Cellular Cardiology*, **2003**, 35, 137-9	5.8	10
18	Decreased ATP-sensitive K(+) current density during chronic human atrial fibrillation. *Journal of Molecular and Cellular Cardiology*, **2003**, 35, 1399-405	5.8	34
17	What is a good tutorial from the student© point of view? Evaluation of tutorials in a newly established PBL block course "Basics of Drug Therapy". *Naunyn-Schmiedebergls Archives of Pharmacology*, **2002**, 366, 69-76	3.4	4
16	Rate-adaptive pacing using intracardiac impedance shows no evidence for positive feedback during dobutamine stress test. *Europace*, **2002**, 4, 311-5	3.9	2
15	Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. *Cardiovascular Research*, **2002**, 54, 397-404	9.9	94
14	Problem-based learning: a new pathway to competence?. *Trends in Pharmacological Sciences*, **2002**, 23, 162-3	13.2	1
13	Ascorbic acid-induced modulation of venous tone in humans. *Hypertension*, **2001**, 37, 949-54	8.5	24
12	Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 1515-25	5.8	99
11	Heterogeneity in hand veins responses to acetylcholine is not associated with polymorphisms in the G-protein beta3-subunit (C825T) and endothelial nitric oxide synthase (G894T) genes but with serum low density lipoprotein cholesterol. *Pharmacogenetics and Genomics*, **2001**, 11, 307-16		18
10	Local venous response to N-desethylamiodarone in humans. *Clinical Pharmacology and Therapeutics* , **2000**, 67, 22-31	6.1	15
9	N-desethylamiodarone modulates intracellular calcium concentration in endothelial cells. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2000**, 362, 489-96	3.4	11
8	Evidence for Edg-3 receptor-mediated activation of I(K.ACh) by sphingosine-1-phosphate in human atrial cardiomyocytes. *Molecular Pharmacology*, **2000**, 58, 449-54	4.3	78
7	The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum. *British Journal of Pharmacology*, **1999**, 127, 576-82	8.6	38
6	Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 302-11	6.1	28
5	Voltage-activated calcium channels involved in veratridine-evoked [3H]dopamine release in rat striatal slices. *Neuropharmacology*, **1998**, 37, 973-82	5.5	13
4	Modulation of potassium-evoked [3H]dopamine release from rat striatal slices by voltage-activated calcium channel ligands: effects of omega-conotoxin-MVIIC. *Neurochemical Research*, **1997**, 22, 1085-93	4.6	14
3	Restriction and functional changes of dopamine release in rat striatum from young adult and old rats. *Mechanisms of Ageing and Development*, **1995**, 80, 107-19	5.6	16

2	Long-term size and range changes of the Griffon Vulture Gyps fulvus population in the Balkans: a review. *Bird Conservation International*,1-16	1.7	3
1	Population reinforcement and demographic changes needed to stabilise the population of a migratory vulture. *Journal of Applied Ecology*,	5.8	1